Level Four Advisory Services’s Mereo BioPharma MREO Stock Holding History

Level Four Advisory Services’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,000	Closed	-$20.6K	–	866
2025 Q3	$20.6K	Hold	10,000	–	–	﹤0.01%	800
2025 Q2	$27.1K	Hold	10,000	–	–	﹤0.01%	782
2025 Q1	$22.5K	Hold	10,000	–	–	﹤0.01%	749
2024 Q4	$35K	Hold	10,000	–	–	﹤0.01%	749
2024 Q3	$42.1K	Hold	10,000	–	–	﹤0.01%	760
2024 Q2	$36K	Sell	10,000 -10,000	-50%	-$32.4K	﹤0.01%	732
2024 Q1	$46.2K	Hold	20,000	–	–	﹤0.01%	758
2023 Q4	$46.2K	Hold	20,000	–	–	﹤0.01%	754
2023 Q3	$25.8K	Hold	20,000	–	–	﹤0.01%	730
2023 Q2	$26.4K	Hold	20,000	–	–	﹤0.01%	792
2023 Q1	$14.1K	Hold	20,000	–	–	﹤0.01%	752
2022 Q4	$15K	Hold	20,000	–	–	﹤0.01%	669
2022 Q3	$17K	Hold	20,000	–	–	﹤0.01%	539
2022 Q2	$22K	Hold	20,000	–	–	﹤0.01%	548
2022 Q1	$22K	Buy	+20,000	New	+$25.9K	﹤0.01%	637

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Level Four Advisory Services's MREO Position: Q4 2025 in Review

Level Four Advisory Services sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 10,000 shares — an estimated $20.6K sold.

Level Four Advisory Services first reported a position in MREO in Q1 2022 and held it in 15 quarters. The position peaked at $46.2K in Q1 2024. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

Level Four Advisory Services reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
Level Four Advisory Services sold 10,000 Mereo BioPharma shares in Q4 2025, an estimated $20.6K.
Level Four Advisory Services first reported a position in Mereo BioPharma in Q1 2022 and held it in 15 quarters.
Level Four Advisory Services's Mereo BioPharma position peaked at $46.2K in Q1 2024.
70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Level Four Advisory Services's 13F filing for Q4 2025, filed 13 Feb 2026.